“We continue to make tremendous progress advancing our clinical programs of INZ-701 in patients with ENPP1 Deficiency and ABCC6 Deficiency, with interim data from both programs expected in September 2023,” said Douglas A. Treco, Ph.D., chief executive officer and chairman of Inozyme’s board of directors. “Notably, following regulatory discussions with the FDA and EMA, we have outlined a clear path forward toward supporting potential regulatory filings in ENPP1 Deficiency.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INZY:
- Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
- Insiders Pour Millions Into These 2 Stocks Under $10 — Here’s Why Wall Street Thinks They Could Double (or More)
- Inozyme director buys $4.0M in common stock
- Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock